NewAmsterdam Pharma Co N.V. (NAMS) Cash Flow Statement
NewAmsterdam Pharma Co N.V. (NAMS) generated -$143.5M of operating cash flow over the twelve months to 2026-06-30, spent $260000 on capital expenditure and had free cash flow of -$143.7M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
NAMSNewAmsterdam Pharma Co N.V.Follow NAMS — free
—
Price chart with a free account
- Market cap
- 2.4B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
| Line | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Operating cash flow | -141.2 | -158.6 | -147.8 | -143.5 | |
| Capital expenditure | 0.0 | 0.7 | 0.2 | -0.3 | |
| Free cash flow | -141.2 | -159.2 | -148.0 | -143.7 | |
| Stock-based compensation | 24.6 | 33.6 | 59.4 | — |
USD millions · SEC XBRL
NewAmsterdam Pharma Co N.V. — questions
- What is NewAmsterdam Pharma Co N.V.'s operating cash flow?
- -$143.5M over the twelve months to 2026-06-30.
- How much does NewAmsterdam Pharma Co N.V. spend on capital expenditure?
- $260000 over the twelve months to 2026-06-30.
- What is NewAmsterdam Pharma Co N.V.'s free cash flow?
- -$143.7M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from NewAmsterdam Pharma Co N.V.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.